D-T7
D-T7 is a transferrin receptor (TfR) binding peptide that mediates brain-targeted delivery. D-T7 acts as a penetration enhancer and uptake promoter for nanoparticles in glioma tissues and target cells. D-T7 can be used in glioma research.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 2350190-98-4
- 分子式: C41H60N14O9
- 分子量:893.00
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
D-T7 peptide-modified PEGylated bilirubin nanoparticles (TBRNPs) (0.12-800 μM) exhibit extremely low cytotoxicity against bEnd.3 mouse brain microvascular endothelial cells, with approximately 80% cell viability observed even at concentrations as high as 10 μM[1].
D-T7 peptide-modified CD&PTX co-loaded PEGylated bilirubin nanoparticles (CD&PTX@TBRNPs) exhibit significantly enhanced cytotoxicity against C6 glioma cells after 24 h, with an IC50 of 1.39 μM (CD concentration), which is 8.78-fold lower than that of unmodified CD&PTX@BRNPs[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:C6 glioma cells
-
Concentration:CD concentrations corresponding to PTX concentrations of 0.2-405 nM
-
Incubation Time:24 h
-
Result:Achieved an IC50 of 1.39 μM (based on CD concentration), which was 8.78-fold lower than the IC50 of CD&PTX@BRNPs.
Single-dose D-T7 peptide-modified nanoparticles selectively accumulate in glioma tissues of Kunming mice bearing C6 glioma, and the brain fluorescence intensity at 24 h post-injection is 7.89-fold higher than that of unmodified nanoparticles[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Kunming mice (male, 20 g)[1]
-
Dosage:Paclitaxel 1.7 mg/kg
-
Administration:i.v.; every 2 days; 6 doses
-
Result:Extended median survival time to 53 days, representing a 231% increase compared to the saline group, and a 23% increase compared to the unmodified CD&PTX@BRNPs group.
Showed the smallest glioma size among all treatment groups.
Exhibited no obvious body weight loss within 20 days of treatment.
Caused no significant toxicity to heart, liver, spleen, lung, or kidney compared to the saline group, with reduced nephrotoxicity relative to free CD&PTX and PTX@BRNPs groups.
Showed hematological parameters mostly within normal ranges, and lower hepatotoxicity than the free CD&PTX group.
化学情報
-
CAS 番号 2350190-98-4
-
分子量 893.00
-
分子式 C41H60N14O9
-
配列
d{HRPYIAH}
-
シーケンスの短縮
d{His-Arg-Pro-Tyr-Ile-Ala-His}
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
D-T7 関連分類
HY-P11918 関連分類
Powered by Bioz
- D-T7
- 2350190-98-4
- Transferrin Receptor
- blood-brain barrier
- transferrin receptor
- blood-brain tumor barrier
- bEnd.3 mouse brain microvascular endothelial cells
- C6 glioma cells
- Kunming mice
- glioma cells
- glioma tissue
- HUVE human umbilical vein endothelial cells
- brain capillary endothelial cells
- Inhibitor
- inhibitor
- inhibit